The Milner Therapeutics Institute connects the intellectual know-how of several large academic institutions with the drug-developing potential of the pharmaceutical industry, to deliver better drugs to the clinic. The Institute was made possible through a £5 million donation from Jonathan Milner and will be located at the Cambridge Biomedical Campus, the centrepiece of the largest biotech cluster outside the United States when it opens in 2018. The outreach programme of the Institute is already active through the Milner Therapeutics Consortium and the Affiliated Company Partnership scheme.
The Milner Therapeutics Institute connects the intellectual know-how of academic institutions in Cambridge with the drug-development capacity of industry to deliver better therapies. The Milner Institute will be in the Capella Building currently being constructed on the Cambridge Biomedical Campus and will have space for senior and junior scientists to set up independent research groups and also communally accessible facilities, such as robotics and bioinformatics. The outreach programme of the Milner Institute is already active through the Milner Therapeutics Consortium and Affiliated Company Partnership Scheme. The Consortium is based on an agreement signed by three academic centers in Cambridge, (Cambridge University, Sanger Institute and Babraham Institute) and four pharmaceutical companies (Astex, AstraZeneca, GlaxoSmithKline and Shionogi).
The key features of the Consortium are:
- An agreement to facilitate the speedy exchange of reagents and information between partners in all therapeutic areas
- The appointment of a dedicated executive to oversee academic/company project engagement
- The development of innovative ideas that would push forward therapeutic boundaries, which will be considered for common funding by industrial partners
The outreach programme also involves an Affiliated Company Partnership Scheme, which allows engagement with service and product providers that are developing tools to advance therapeutic development. The Institute encourages and coordinates interactions of affiliated companies with the pharmaceutical and academic partners, towards communal project development. The Milner Therapeutics Institute and Consortium are led by Professor Tony Kouzarides, Deputy Director of the Gurdon Institute and the Consortium is managed by Dr Kathryn Chapman. For more information please go to www.milner.cam.ac.uk.